^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NBF-006

    i
    Other names: NBF-006, NBF 006, NBF006
    Associations

    News

    Trials
    Company:
    Nitto Denko
    Drug class:
    Glutathione S transferase P inhibitor, RNA interference
    Related drugs:
    Associations

    News

    Trials
    28d
    A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer. (PubMed, Mol Cancer Ther)
    The lead drug product candidate (NBF-006) is a proprietary siRNA-based lipid nanoparticle (LNP) comprising GSTP siRNA (NDT-05-1040). Additionally, in a surgically implanted orthotopic lung tumor model, the survival rate of the NBF-006 treatment group was significantly prolonged (P <0.005) as compared to the vehicle control group. Together, these preclinical studies supported advancement of NBF-006 into clinical studies.
    Journal • PARP Biomarker • Lipid Nanoparticle
    |
    KRAS (KRAS proto-oncogene GTPase) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • PCNA (Proliferating cell nuclear antigen)
    |
    KRAS mutation
    |
    NBF-006
    4ms
    A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (clinicaltrials.gov)
    P1, N=49, Completed, Nitto BioPharma, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024 | Trial primary completion date: Mar 2024 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    NBF-006
    1year
    First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer. (AACR-NCI-EORTC 2023)
    No abstract available
    Clinical • P1 data
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    NBF-006
    1year
    Enhanced growth inhibition in lung cancer cells through NBF-006 combination therapy with chemotherapy or KRAS inhibitors. (AACR-NCI-EORTC 2023)
    No abstract available
    Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    NBF-006
    1year
    First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS- mutated non-small cell lung cancer* (AACR-NCI-EORTC 2023)
    No abstract available
    Clinical • P1 data
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    NBF-006
    1year
    A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Nitto BioPharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    NBF-006
    over1year
    A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (clinicaltrials.gov)
    P1, N=44, Recruiting, Nitto BioPharma, Inc. | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    NBF-006
    over3years
    A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (clinicaltrials.gov)
    P1, N=44, Recruiting, Nitto BioPharma, Inc. | N=30 --> 44 | Trial completion date: Aug 2021 --> Mar 2023 | Trial primary completion date: Feb 2021 --> Aug 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    NBF-006